10-K: Zentalis Pharmaceuticals Focuses on Azenosertib Amid Restructuring

Zentalis Pharmaceuticals, Inc. reported a net loss of $137.1 million for 2025, narrowing from $165.9 million in 2024, as it strategically restructured to prioritize its lead oncology candidate, azenosertib, and extend its cash runway into late 2027.

Summary

• Zentalis is a clinical-stage biopharmaceutical company primarily focused on developing azenosertib (ZN-c3), a WEE1 inhibitor, for Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
• The company completed enrollment in Part 2a of its Phase 2 DENALI clinical trial in 2025, with a topline readout anticipated by year-end 2026, which, if successful, has the potential to support accelerated FDA approval.
• A Phase 3 confirmatory trial, ASPENOVA, is planned for initiation in the first half of 2026 and will enroll concurrently with DENALI Part 2b.
• Clinical data from DENALI Part 1b (n=102) showed an Objective Response Rate (ORR) of 34.9% (15/43) in response-evaluable Cyclin E1-positive PROC patients, with a median Duration of Response (mDOR) of approximately 6.3 months as of January 13, 2025.
• The company reported a net loss of $137.1 million for the year ended December 31, 2025, an improvement from a $165.9 million net loss in 2024.
• Cash, cash equivalents, and marketable securities totaled $245.9 million as of December 31, 2025, which is expected to fund operating expenses and capital expenditure requirements into late 2027.
• A strategic restructuring in January 2025 resulted in a workforce reduction of approximately 40% and incurred $7.8 million in restructuring expenses.
• The company repurchased 7,500,000 shares of common stock from Matrix Capital Master Fund, LP at $1.33 per share on December 15, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for Zentalis, marked by significant losses and a strategic narrowing of its pipeline, despite some positive clinical data and a clear path for its lead candidate, azenosertib. The need for substantial future capital raises and the workforce reduction indicate ongoing financial pressures.

Positives

• Net loss decreased to $137.1 million in 2025 from $165.9 million in 2024, indicating a reduction in operating losses.
• Cash, cash equivalents, and marketable securities of $245.9 million as of December 31, 2025, are projected to fund operations into late 2027, extending the cash runway.
• Azenosertib received Fast Track Designation from the FDA for Cyclin E1-positive PROC, potentially expediting development and review.
• Enrollment for DENALI Part 2a was completed in 2025, with dose selection expected in the first half of 2026 and topline readout by year-end 2026, demonstrating progress in clinical development.
• The Phase 3 ASPENOVA confirmatory trial design has been aligned with the FDA and is planned for initiation in the first half of 2026, supporting a path to full approval.
• DENALI Part 1b data showed a 34.9% Objective Response Rate (ORR) in Cyclin E1-positive PROC patients and a manageable safety profile, suggesting therapeutic potential.
• The median Duration of Response (mDOR) for DENALI Part 1b increased to approximately 6.3 months as of January 13, 2025, indicating sustained responses.
• The company is actively developing a companion diagnostic for Cyclin E1-positive PROC, with a prototype ready for Phase 3, which is crucial for biomarker-directed therapy.
• The global ovarian cancer market was approximately $3 billion in 2022, with significant expected growth, presenting a large market opportunity for azenosertib.
• The estimated less than 20% overlap between FR-high PROC patients and Cyclin E1-positive PROC patients highlights a significant unmet need that azenosertib could address.
• The azenosertib partial clinical hold announced in June 2024 was lifted in September 2024 without any changes required by the FDA to the clinical development plan.

Negatives

• The company has incurred significant net losses since inception, with an accumulated deficit of $1.2 billion as of December 31, 2025.
• No products are approved for commercial sale, and no revenue has been generated from product sales to date.
• Substantial additional capital will be required to finance operations beyond late 2027, indicating a reliance on future funding.
• The company is substantially dependent on the success of azenosertib, its only product candidate currently in clinical development, increasing business risk.
• Further development of azenosertib in combination with niraparib was discontinued because efficacious exposures of azenosertib were not reached.
• The company decided not to advance to the dose expansion phase of the azenosertib combination study with encorafenib and cetuximab due to resource prioritization and an evolving treatment landscape.
• Further development of azenosertib in uterine serous carcinoma (USC) has been discontinued.
• A goodwill impairment charge of $3.7 million was recorded in 2024.
• Restructuring expenses of $7.8 million were incurred in 2025 due to a workforce reduction of approximately 40%, reflecting cost-cutting measures.
• The company repurchased 7,500,000 shares of common stock from Matrix Capital Master Fund, LP at $1.33 per share, representing a discount from the closing share price of $1.40 on December 12, 2025.

Risks

• Limited operating history and no products approved for commercial sale make it difficult to evaluate current business and predict future success and viability.
• Expect to continue incurring significant net losses for the foreseeable future, impacting working capital and profitability.
• Will require substantial additional capital to finance operations; inability to raise funds could delay, reduce, or eliminate research and drug development programs or commercialization efforts.
• Substantially dependent on the success of azenosertib; any setbacks in its development or commercialization could materially harm the business.
• Clinical trials of azenosertib or any future product candidates may not demonstrate safety and efficacy to the satisfaction of regulatory authorities or otherwise produce positive results.
• Required to obtain approval of a companion diagnostic for azenosertib's lead indication; delays or failure to obtain approval would materially impair commercialization and revenue generation.
• The regulatory approval processes of the FDA and ex-U.S. regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Face significant competition from major pharmaceutical and biotechnology companies, which could negatively impact commercial opportunities.
• Success depends on the ability to protect intellectual property; inadequate protection could harm the competitive position.
• Reliance on third parties (CROs, CMOs) to conduct preclinical studies, clinical trials, and manufacturing increases risks of delays, non-compliance, or insufficient supply.
• Commercial success depends on operating without infringing third-party patents; claims of infringement could result in liability or delay development.
• Intense competition for qualified personnel; inability to attract and retain key personnel could harm business execution.
• Unfavorable U.S., global, political, or economic conditions (e.g., inflation, military conflicts) could adversely affect business, financial condition, or results of operations.
• Business interruptions (e.g., natural disasters, cyberattacks) could adversely affect operations.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited due to ownership changes or tax laws.
• Risks associated with marketing product candidates internationally, including differing regulatory requirements, price controls, and political instability.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, cause debt, or subject the company to other risks.
• Requirements of being a public company may strain resources, result in more litigation, and divert management's attention.
• A portion of manufacturing takes place in ex-U.S. countries (e.g., China), exposing the company to supply disruptions, trade wars, and political unrest.
• Significant risk of product liability claims, which could delay development, lead to recalls, or result in substantial monetary awards.
• Any approved product candidates may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
• Current and future healthcare reform legislation or regulation may increase the difficulty and cost of commercialization and adversely affect prices.
• Relationships with healthcare professionals, clinical investigators, and third-party payors may be subject to fraud and abuse laws and other healthcare regulations.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws could adversely affect business.
• Employees, independent contractors, and collaborators may engage in misconduct or other improper activities.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Research and development activities could be affected or delayed by possible restrictions on animal testing.
• Business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery laws, as well as export controls and trade sanctions.
• The price of common stock may be volatile, and quarterly operating results may fluctuate significantly.
• Principal stockholders and management own a significant percentage of stock and can exert significant influence over matters subject to stockholder approval.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to product candidates on unfavorable terms.
• If securities or industry analysts do not publish research or reports, or publish adverse reports, stock price and trading volume could decline.
• Provisions in the certificate of incorporation and bylaws and Delaware law might discourage, delay, or prevent a change in control or management changes.
• The certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Do not currently intend to pay dividends on common stock; ability to achieve a return on investment depends on stock appreciation.
• Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud.
• May be subject to securities litigation, which is expensive and could divert management attention.
• Patent terms may be inadequate to protect the competitive position for an adequate amount of time.
• May not be able to protect intellectual property rights throughout the world.
• Inability to protect trade secrets could harm business and competitive position.
• May be subject to claims of wrongful hiring or wrongful use/disclosure of confidential information or trade secrets of former employers.

Future Outlook

Zentalis anticipates a topline readout for the DENALI Part 2 clinical trial by year-end 2026, which, if successful, has the potential to support an accelerated approval for azenosertib in Cyclin E1-positive PROC. The company plans to initiate the Phase 3 ASPENOVA confirmatory study in the first half of 2026, enrolling concurrently with DENALI Part 2b. Zentalis also plans to advance azenosertib development in other tumor types and evaluate additional strategic opportunities as resources allow.

Management Comments

• We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, has the potential to support an accelerated approval, subject to U.S. Food and Drug Administration, or FDA, review.
• We believe azenosertib has the potential to set a new standard of care in patients with Cyclin E1-positive PROC.
• We believe that the opportunity for azenosertib is broad, and we plan to advance the clinical development of azenosertib outside of Cyclin E1-positive PROC, as our resources allow.
• We are proud of the diversity we have cultivated throughout the company and our management team.
• We are dedicated to supporting a talented team and strive to offer competitive compensation, including salaries, bonuses and equity awards, and benefits in order to support our business objectives, assist in the achievement of our strategic goals and create value for our stockholders.
• Our management team, including our Chief Executive Officer, our Chief Legal Officer and our Vice President, Information Technology, is responsible for assessing and managing our risks from cybersecurity threats.

Industry Context

StockSavvy.ai notes that Zentalis's focus on azenosertib as a WEE1 inhibitor for Cyclin E1-positive PROC aligns with the growing industry trend towards biomarker-directed therapies in oncology, similar to the successful launch of mirvetuximab for FR-high PROC patients. The company's strategic restructuring and prioritization of a single lead candidate reflect a common industry response to capital constraints and the need to focus resources on the most promising assets in a competitive biopharmaceutical landscape. The discontinuation of certain combination trials and other indications also highlights the intense resource allocation decisions faced by clinical-stage companies.

Comparison to Industry Standards

• Zentalis's reported ORR of 34.9% for azenosertib in Cyclin E1-positive PROC patients from DENALI Part 1b compares favorably to the 'modest clinical benefits' typically seen with standard-of-care single-agent chemotherapy in PROC patients, as stated in the filing.
• The successful launch of mirvetuximab in FR-high PROC patients demonstrates a precedent for biomarker-directed therapies in this market, suggesting a similar potential path for azenosertib in Cyclin E1-positive PROC, a distinct patient population with less than 20% overlap.
• The global ovarian cancer market of approximately $3 billion in 2022, with expected growth, provides a substantial target for azenosertib, positioning it within a high-value segment of oncology.
• The company faces competition from other WEE1 inhibitors in clinical development, such as Debiopharm's Debio 0123, Bristol-Myers Squibb's BMS-986463, Aprea's APR-1051, Schrdinger's SGR-3515, Acrivon's ACR-2316, Impact Therapeutics' IMP7068, Shouyao Holdings' SY-4835, WuXi AppTec's SC0191, and Wigen Biomedicine Technology's WJB001, indicating a competitive but active development space for this mechanism of action.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not subject to any material legal proceedings.

Related Party Transactions

• On December 15, 2025, the company repurchased 7,500,000 shares of its common stock from Matrix Capital Master Fund, LP, one of its then-stockholders, at a price of $1.33 per share.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings, stock price volatility, influence from principal stockholders, and no anticipated cash dividends.
• Employees experienced a workforce reduction of approximately 40% in January 2025, but the company strives to offer competitive compensation, benefits, and development opportunities.
• Patients may benefit from the continued development of azenosertib for ovarian cancer, with potential for accelerated approval and a new standard of care, though clinical trial risks remain.
• Future customers will be impacted by the market acceptance, pricing, and reimbursement of any approved products.
• Suppliers and creditors may face strain due to general economic downturns, and the company's reliance on third-party manufacturers introduces supply chain risks.

Next Steps

• Announce dose selection from DENALI Part 2a in the first half of 2026.
• Initiate Phase 3 ASPENOVA confirmatory clinical trial in the first half of 2026, enrolling concurrently with DENALI Part 2b.
• Anticipate a topline readout for DENALI Part 2 by year-end 2026.
• Continue enrolling patients in the MUIR (ZN-c3-002) Phase 1b clinical trial evaluating azenosertib in combination with bevacizumab.
• Publish results from the TETON (ZN-c3-004) Phase 2 clinical trial in uterine serous carcinoma in the future (though no further development is planned for this indication).
• Validate a companion diagnostic test for Cyclin E1-positive PROC with a diagnostic partner.
• Evaluate additional strategic opportunities to maximize pipeline value.
• Identify and qualify additional manufacturers for azenosertib.
• Monitor regulatory developments, including the BIOSECURE Act and the list of designated biotechnology companies of concern expected by December 2026.

Key Dates

Recommendation

Zentalis is at a critical juncture, having narrowed its focus to a single lead asset, azenosertib, with promising early clinical data and Fast Track designation. While the potential for accelerated approval in Cyclin E1-positive PROC is a significant positive, the company's substantial accumulated deficit, ongoing net losses, and the need for significant additional capital beyond late 2027 present considerable financial risks. The recent workforce reduction and share repurchase from a major stockholder, while extending the cash runway, underscore these challenges. Investors should hold to monitor the upcoming DENALI Part 2 topline readout by year-end 2026 and the initiation of the Phase 3 ASPENOVA trial in H1 2026, as these milestones will be crucial in de-risking the investment and determining the long-term commercial viability of azenosertib.

Keywords

Zentalis Pharmaceuticals, azenosertib, WEE1 inhibitor, ovarian cancer, Cyclin E1-positive, platinum-resistant ovarian cancer, PROC, DENALI clinical trial, ASPENOVA clinical trial, biopharmaceutical, oncology, clinical-stage, FDA Fast Track, companion diagnostic, drug development, SEC filing, 10-K, financial results, strategic restructuring, biomarker-directed therapy, equity awards, capital raise, stock repurchase